Competitiveness / Health Care

This section feature research, opinion and progress reports on how the Czech Republic compares to other EU countries economically. It includes analysis of international rankings such as the WEF and World Bank.

Spotlight issue

29th July 2020 / Competitiveness / Health Care


How Pfizer and BioNTech are moving with safety and speed to develop a potential COVID-19 vaccine

Since Pfizer and our collaboration partner, BioNTech, begun our mission to develop a COVID-19 vaccine, safety has been our guiding principle every step of the way. At the same time, given the urgency of the global pandemic, we continue to move at record-breaking speed. We recently started the phase 2/3 safety and efficacy trial for our lead vaccine candidate, approximately three months after we started the phase 1/2 safety and immunogenicity trials in Germany and the United States for our four initial vaccine candidates.  Progressing from the start of clinical testing for a vaccine candidate in small numbers of trial participants to a large-scale efficacy trial is a process that can usually take years, sometimes even a decade.
View more

17th June 2020 / Competitiveness / Health Care


AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s potential COVID-19 vaccine

Company exploring further additional global capacity to provide broad and equitable access at no profit during the pandemic
View more

6th May 2020 / Competitiveness / Health Care


Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021  
View more

22nd April 2020 / Competitiveness / Health Care


BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates

First COVID-19-related clinical trial to start in Germany Initial dose escalation phase to target dose range of 1µg to 100µg Clinical supply from BioNTech’s GMP-certified mRNA production facilities in Europe Four vaccine candidates to enter clinical development
View more

Members of the American Chamber of Commerce in the Czech Republic